IHP 515 Module 5 Milestone Two Example

Milestone Two: What the Evidence Shows About Naloxone and Treatment After Overdose

[Student Name]

Southern New Hampshire University

IHP 515: Population-Based Epidemiology

Module Five Milestone Two

[Instructor Name]

[Date]

Milestone Two: What the Evidence Shows About Naloxone and Treatment After Overdose

The descriptive epidemiology of overdose deaths in Harlan County pointed to two opportunities: most people died where no one gave naloxone, and treatment with methadone or buprenorphine was rare, even among people who had overdosed before. This milestone reviews evidence on two interventions that address those gaps, community naloxone distribution and medication treatment after nonfatal overdose. For each, it considers the study design, the findings, the likely biases and how much confidence the evidence deserves.

Community Naloxone Distribution

Walley et al. (2013) evaluated overdose education and naloxone distribution programs in Massachusetts using an interrupted time series analysis of nineteen communities, comparing overdose death rates before and after programs began and between communities with different levels of implementation. Communities with programs had lower opioid overdose death rates than those without, and communities with higher implementation, measured by enrollments per population, showed larger reductions, after adjustment for factors such as poverty, prescription rates and treatment availability.

The design is observational, so communities were not randomly assigned to programs, and unmeasured differences could explain part of the association. However, the dose-response pattern, in which more implementation was linked to larger reductions, and the use of comparison communities strengthen the case that naloxone distribution contributed to the decline.

A Systematic Review of Take-Home Naloxone

McDonald and Strang (2016) systematically reviewed studies of take-home naloxone programs and assessed whether the evidence supported a causal effect on overdose mortality using the Bradford Hill criteria, such as strength, consistency, temporality, dose-response and plausibility. They found that take-home naloxone programs were associated with reduced overdose mortality among participants and in communities, that most overdose reversals by trained bystanders were successful and that adverse events were rare. No randomized trials were available, but the consistency of findings across settings and the clear biological mechanism led them to judge that the criteria were largely satisfied.

Treatment After Nonfatal Overdose

Larochelle et al. (2018) followed a cohort of more than 17,000 adults in Massachusetts who survived an opioid overdose, linking state records on treatment and deaths. In the year after overdose, only a minority received methadone, buprenorphine or naltrexone. Receipt of methadone and buprenorphine was associated with substantially lower all-cause mortality and opioid-related mortality compared with no medication, while naltrexone was not associated with lower mortality. The authors adjusted for many factors and analyzed treatment as it changed over time.

As an observational cohort, the study cannot rule out residual confounding; people who enter and stay in treatment may differ in ways that also protect them. Yet the size of the associations, their consistency with randomized trials of these medications for other outcomes and the plausible mechanism make the findings compelling. The study also shows how often the window after an overdose is missed.

Why Randomized Trials Are Scarce

All three studies are observational, which invites the question of why stronger designs are not available. Randomizing communities to receive or not receive naloxone would be difficult to organize and hard to justify ethically once evidence of benefit emerged, since withholding a lifesaving drug from control communities could cost lives. Randomizing overdose survivors to no medication treatment would face the same objection, given randomized trials already showing that methadone and buprenorphine reduce illicit opioid use. Epidemiologists therefore rely on well-designed observational studies, such as interrupted time series with comparison groups and large cohorts with careful adjustment, and on criteria such as those Hill proposed to judge causation. Recognizing this context helps avoid dismissing good evidence simply because it is not experimental.

Synthesis

Both interventions have consistent observational evidence of benefit, supported by strong mechanisms: naloxone reverses opioid overdose, and methadone and buprenorphine reduce illicit opioid use and overdose risk. Neither has been tested in large randomized trials of community-level mortality, which would be difficult and arguably unethical. For decision makers, the question is not whether the evidence is perfect but whether it is strong enough to act, and by the standards public health usually applies, it is.

Table 1. Evidence Summary

Note. Designs are described as reported by the authors.

Gaps

The studies come largely from Massachusetts and urban areas, while Harlan includes rural areas with long emergency response times. Little evidence addresses how best to reach people who use alone, the largest group of Harlan's deaths. And evidence on engaging people in treatment after jail release, a key risk period in the county, comes from different study populations. These gaps call for careful local evaluation of any program the county adopts.

Other Interventions Considered

The review focused on two interventions, but others deserve mention. Fentanyl test strips, which let people check drugs before use, have growing use but limited outcome evidence. Programs that pair peer recovery coaches with emergency department patients after overdose show promise in linking people to treatment. Prescription drug monitoring and prescribing limits addressed the earlier, prescription-driven phase of the epidemic but are less relevant to deaths now driven by illicit fentanyl. Harlan may consider these as complements, with evaluation, while placing naloxone and medication treatment at the center of its plan.

Implications for Harlan County

The evidence supports three actions: broad naloxone distribution with emphasis on households and rural areas, programs that start medication treatment in emergency departments and at jail release and follow-up outreach after nonfatal overdoses. Given the dose-response pattern in the naloxone study, distribution should be ambitious rather than token. Because the evidence is observational, the county should monitor overdose deaths and treatment uptake closely to confirm local benefit.

Conclusion

Community naloxone distribution and medication treatment after overdose are supported by consistent observational evidence, plausible mechanisms and, for naloxone, a systematic application of causal criteria. The evidence is strong enough to act on, and the gaps it leaves point to what Harlan County should evaluate as it acts.

References

Larochelle, M. R., Bernson, D., Land, T., Stopka, T. J., Wang, N., Xuan, Z., Bagley, S. M., Liebschutz, J. M., & Walley, A. Y. (2018). Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: A cohort study. Annals of Internal Medicine, 169(3), 137-145. https://doi.org/10.7326/M17-3107

McDonald, R., & Strang, J. (2016). Are take-home naloxone programmes effective? Systematic review utilizing application of the Bradford Hill criteria. Addiction, 111(7), 1177-1187. https://doi.org/10.1111/add.13326

Walley, A. Y., Xuan, Z., Hackman, H. H., Quinn, E., Doe-Simkins, M., Sorensen-Alawad, A., Ruiz, S., & Ozonoff, A. (2013). Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: Interrupted time series analysis. BMJ, 346, Article f174. https://doi.org/10.1136/bmj.f174